$15.45
+0.38
(+2.52%)▲
2.59%
Downside
Day's Volatility :5.41%
Upside
2.9%
21.49%
Downside
52 Weeks Volatility :49.56%
Upside
35.76%
Period | Fonar Corp | |
---|---|---|
3 Months | -34.85% | |
6 Months | -22.2% | |
1 Year | -12.84% | |
3 Years | -18.72% |
Market Capitalization | 97.3M |
Book Value | $25.68 |
Earnings Per Share (EPS) | 1.57 |
PE Ratio | 9.6 |
PEG Ratio | 0.0 |
Profit Margin | 10.68% |
Operating Margin TTM | 14.57% |
Return On Assets TTM | 5.41% |
Return On Equity TTM | 9.52% |
Revenue TTM | 102.7M |
Revenue Per Share TTM | 15.91 |
Quarterly Revenue Growth YOY | 1.2% |
Gross Profit TTM | 45.7M |
EBITDA | 22.4M |
Diluted Eps TTM | 1.57 |
Quarterly Earnings Growth YOY | -0.49 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 81.5M | ↑ 4.46% |
Net Income | 21.2M | ↑ 8.21% |
Net Profit Margin | 26.04% | ↑ 0.9% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 87.2M | ↑ 6.96% |
Net Income | 20.5M | ↓ 3.38% |
Net Profit Margin | 23.53% | ↓ 2.51% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 85.7M | ↓ 1.72% |
Net Income | 11.7M | ↓ 42.94% |
Net Profit Margin | 13.66% | ↓ 9.87% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 89.9M | ↑ 4.95% |
Net Income | 13.7M | ↑ 16.82% |
Net Profit Margin | 15.2% | ↑ 1.54% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 97.6M | ↑ 8.52% |
Net Income | 17.2M | ↑ 26.04% |
Net Profit Margin | 17.66% | ↑ 2.46% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 98.6M | ↑ 1.08% |
Net Income | 9.4M | ↓ 45.6% |
Net Profit Margin | 9.5% | ↓ 8.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 24.3M | ↑ 4.59% |
Net Income | 2.2M | ↑ 16.07% |
Net Profit Margin | 9.2% | ↑ 0.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.4M | ↑ 4.81% |
Net Income | 3.9M | ↑ 72.94% |
Net Profit Margin | 15.18% | ↑ 5.98% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.8M | ↑ 1.39% |
Net Income | 1.2M | ↓ 67.96% |
Net Profit Margin | 4.8% | ↓ 10.38% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.0M | ↓ 92.15% |
Net Income | 8.7M | ↑ 603.44% |
Net Profit Margin | 430.05% | ↑ 425.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.4M | ↑ 1154.87% |
Net Income | 3.8M | ↓ 56.79% |
Net Profit Margin | 14.81% | ↓ 415.24% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 25.7M | ↑ 1.31% |
Net Income | 1.9M | ↓ 50.2% |
Net Profit Margin | 7.28% | ↓ 7.53% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 118.3M | ↑ 19.79% |
Total Liabilities | 16.1M | ↑ 1.41% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 133.6M | ↑ 12.89% |
Total Liabilities | 15.4M | ↓ 3.91% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 180.3M | ↑ 34.96% |
Total Liabilities | 54.0M | ↑ 249.67% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 189.5M | ↑ 5.13% |
Total Liabilities | 54.1M | ↑ 0.22% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 199.3M | ↑ 5.19% |
Total Liabilities | 53.1M | ↓ 1.9% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 200.6M | ↑ 0.62% |
Total Liabilities | 49.8M | ↓ 6.31% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 197.5M | ↓ 0.26% |
Total Liabilities | 49.4M | ↓ 2.88% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 199.3M | ↑ 0.93% |
Total Liabilities | 48.7M | ↓ 1.43% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 200.6M | ↑ 0.63% |
Total Liabilities | 49.8M | ↑ 2.13% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 201.6M | ↑ 0.49% |
Total Liabilities | 47.5M | ↓ 4.57% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 202.3M | ↑ 0.35% |
Total Liabilities | 46.0M | ↓ 3.2% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 209.6M | ↑ 3.64% |
Total Liabilities | 52.6M | ↑ 14.44% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 18.7M | ↑ 11.5% |
Investing Cash Flow | -2.9M | ↓ 31.81% |
Financing Cash Flow | -6.3M | ↓ 42.08% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 19.4M | ↑ 3.78% |
Investing Cash Flow | -18.6M | ↑ 530.84% |
Financing Cash Flow | -6.6M | ↑ 5.1% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 20.4M | ↑ 4.91% |
Investing Cash Flow | 7.4M | ↓ 139.95% |
Financing Cash Flow | -4.9M | ↓ 25.93% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 19.1M | ↓ 6.44% |
Investing Cash Flow | -4.8M | ↓ 164.93% |
Financing Cash Flow | -6.6M | ↑ 34.77% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 15.3M | ↓ 19.84% |
Investing Cash Flow | -5.2M | ↑ 7.46% |
Financing Cash Flow | -5.9M | ↓ 11.36% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.5M | ↓ 5.45% |
Investing Cash Flow | -4.3M | ↓ 16.24% |
Financing Cash Flow | -7.6M | ↑ 29.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.2M | ↑ 17.35% |
Investing Cash Flow | -473.0K | ↓ 50.88% |
Financing Cash Flow | -1.9M | ↑ 6.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.3M | ↑ 35.45% |
Investing Cash Flow | -2.2M | ↑ 365.96% |
Financing Cash Flow | -1.9M | ↑ 3.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.3M | ↑ 0.73% |
Investing Cash Flow | -698.1K | ↓ 68.32% |
Financing Cash Flow | -2.0M | ↑ 1.66% |
Sell
Neutral
Buy
Fonar Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Fonar Corp | -14.42% | -22.2% | -12.84% | -18.72% | -23.58% |
Idexx Laboratories, Inc. | 3.26% | -4.68% | 5.84% | -11.81% | 94.73% |
Agilent Technologies Inc. | -6.55% | 1.96% | 11.03% | -4.71% | 93.38% |
Thermo Fisher Scientific, Inc. | -0.69% | 14.99% | 9.83% | 26.92% | 112.55% |
Danaher Corp. | 5.65% | 19.11% | 12.12% | 8.8% | 94.77% |
Iqvia Holdings Inc. | -4.66% | 0.09% | 6.11% | -7.43% | 59.67% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Fonar Corp | 9.6 | 9.6 | 0.0 | 0.0 | 0.1 | 0.05 | NA | 25.68 |
Idexx Laboratories, Inc. | 48.52 | 48.52 | 4.75 | 11.05 | 0.72 | 0.23 | NA | 18.93 |
Agilent Technologies Inc. | 30.83 | 30.83 | 2.7 | 5.27 | 0.21 | 0.08 | 0.01 | 21.31 |
Thermo Fisher Scientific, Inc. | 36.5 | 36.5 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 119.24 |
Danaher Corp. | 47.21 | 47.21 | 3.13 | 7.61 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 29.57 | 29.57 | 1.33 | 11.08 | 0.22 | 0.05 | NA | 34.82 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Fonar Corp | NA | $97.3M | -23.58% | 9.6 | 10.68% |
Idexx Laboratories, Inc. | Buy | $41.3B | 94.73% | 48.52 | 23.26% |
Agilent Technologies Inc. | Buy | $38.0B | 93.38% | 30.83 | 18.84% |
Thermo Fisher Scientific, Inc. | Buy | $216.8B | 112.55% | 36.5 | 14.2% |
Danaher Corp. | Buy | $190.2B | 94.77% | 47.21 | 18.55% |
Iqvia Holdings Inc. | Buy | $39.4B | 59.67% | 29.57 | 9.01% |
Kayne Anderson Rudnick Investment Management LLC
Dimensional Fund Advisors, Inc.
Vanguard Group Inc
MONEY CONCEPTS CAPITAL CORP
Renaissance Technologies Corp
LSV Asset Management
manufacturer of state-of-the-art mri equipment located in melvillle new york.
Organization | Fonar Corp |
Employees | 561 |
CEO | Mr. Timothy R. Damadian M.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$15.45
+2.52%
Keyarch Acquisition Corp
$15.45
+2.52%
Connexa Sports Technologies Inc
$15.45
+2.52%
Us Value Etf
$15.45
+2.52%
First Wave Biopharma Inc
$15.45
+2.52%
Global X Msci Next Emerging
$15.45
+2.52%
Fat Projects Acquisition Corp
$15.45
+2.52%
Goal Acquisitions Corp
$15.45
+2.52%
Capital Link Global Fintech
$15.45
+2.52%